Imipramine Blue

A potent STAT5 inhibitor with a dual mechanism of action, potently inhibits STAT5 through liberation of endogenous phosphatase activity following NADPH oxidase (NOX) inhibition at 200-300 nM; effectively kills mutant FLT3-driven AML cells through a similar mechanism as thapsigargin (TG), involving increased cytosolic calcium, at 75-150 nM; a novel anti-invasive small molecule that inhibits invasion of glioma in vitro.

References 1. Metts J, et al. Sci Rep. 2017 Jun 30;7(1):4447. 2. Rajamanickam S, et al. Clin Cancer Res. 2016 Jul 15;22(14):3524-36. 3. Munson JM, et al. Sci Transl Med. 2012 Mar 28;4(127):127ra36. 4. Yang WH, et al. Oncogene. 2016 May 5;35(18):2287-98. View Related Products by Target NADPH Oxidase (NOX)